InnotiveDx Secures £1 Million Grant to Revolutionize UTI Diagnostics Technology

InnotiveDx Secures £1 Million Grant to Enhance UTI Diagnostics

Innotive Diagnostics, known as InnotiveDx, has just announced that it has successfully secured a substantial grant of £1 million from PACE, which stands for Pathways to Antimicrobial Clinical Efficacy. This funding represents a significant milestone for the company as it aims to enhance the development of its innovative rapid point-of-care diagnostic system specifically for urinary tract infections (UTIs).

UTIs are a prevalent health issue, affecting millions of people worldwide and representing a substantial burden on healthcare systems, leading to over 20% of total antibiotic prescriptions. The potential for antimicrobial resistance (AMR) is particularly concerning, given that these infections contribute significantly to the overall healthcare costs associated with unplanned hospital admissions, amounting to billions of dollars globally.

InnotiveDx has pioneered a unique diagnostic technology that promises to deliver highly accurate Bacterial identification and antimicrobial susceptibility (AST) test results in under 60 minutes. According to blinded evaluations, the accuracy of their benchtop assay exceeds 96%. Having developed automated prototypes, the newly acquired PACE grant will enable InnotiveDx to rigorously assess the reliability and accuracy of its systems with thousands of clinical specimens. Following this step, they will transition into real-world pilot studies, providing invaluable data and insights.

James Mainwaring, the Chief Commercial and Operating Officer of InnotiveDx, shares his enthusiasm, stating, "We are thrilled to have been awarded this £1m PACE grant; it validates not only our technology and vision but also the dedicated effort of our team since the company's inception. Tackling AMR is among the most urgent challenges facing humanity today, and we are keen to collaborate with PACE and their network of partners to address it effectively."

Dr. Beverley Isherwood, PACE Programme Director, expressed her delight by stating, "Congratulations to Innotive Diagnostics! We are excited to welcome them into the PACE portfolio after a highly competitive funding round. Leveraging a collaborative approach, PACE aims to assist InnotiveDx in advancing their InnotiveUTI testing system and obtaining the essential validation data required for further development and investment opportunities."

The Objective Behind the Technology

InnotiveDx is dedicated to revolutionizing the field of diagnostics, particularly through the development of its InnotiveUTI test. This rapid-testing system aims to diagnose UTIs effectively within just sixty minutes at the point of care—an area currently underserved in rapid diagnostics. By accurately identifying causative bacteria and their susceptibility patterns, the InnotiveUTI test could drastically improve antimicrobial stewardship and patient outcomes.

About PACE

PACE is recognized as one of the UK’s most significant public-private initiatives, designed to catalyze early-stage antimicrobial drug and diagnostic discovery. The collaboration involves Innovate UK, LifeArc, and Medicines Discovery Catapult, all of whom are focused on addressing the pressing health issues surrounding infections that have the highest burden of AMR.

In summary, this grant represents a groundbreaking opportunity for InnotiveDx to enhance public health responses to UTIs through innovative diagnostics continuously. As antimicrobial resistance continues to pose a significant threat to healthcare systems worldwide, companies like InnotiveDx, equipped with the right technology and backing, will play a crucial role in combating this crisis.